Last February, Northwest Biotherapeutics (NWBO), the Maryland-based company developing an experimental brain cancer treatment called DCVax, said that it had collected enough clinical trial data to determine whether its vaccine could delay the growth of tumors longer than standard of care.
In other words, the randomized, controlled study was ready to be analyzed.
About the Author Reprints
